ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
2017 March Provider Press
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 16, 2017
လံာ်တီလံာ်မီတဖၣ်ဒီး လံာ်ကွီၣ်ဒိတဖၣ်အစၢတဖၣ်
တၢ်ပာ်ဖျါ 3041 - 3050 လၢ 3159 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P5-17 Updated: Third Party Payments of Premium and/or Cost-Sharing
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဖ့ၤဘြူၤအါရံၤ 08, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P4-17 Addition of Drug to the Self-Administered Oncology Prior Authorization with Quantity Limit Program
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 30, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P2-17 Updated: Change in Coverage for Detoxification Services for Minnesota Health Care Programs Subscribers
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 27, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P3-17 Added Reimbursement Policies
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 27, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P1-17 Prior Authorization Requirement for Gender Dysphoria
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 18, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP1-17 2017 Commercial Network Guide
တၢ်ရဲၣ်တၢ်ကျၢၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါယနူၤအါရံၤ 09, 2017
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
P63-16 Drug Related Prior Authorization Criteria Changes for Ampyra, H.P. Acthar Gel, Transmucosal Fentanyl, Growth Hormone, and Oral Pulmonary Arterial Hypertension Agents
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဒံၣ်စဲဘၢၣ် 20, 2016
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP39-16 Digital Breast Tomosynthesis (DBT) for Routine Breast Cancer Screening
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဒံၣ်စဲဘၢၣ် 15, 2016
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP40-16 Medicare Outpatient Observation Notice (MOON) CMS-10611
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲအမုၢ်နံၤမုၢ်သီ- လါဒံၣ်စဲဘၢၣ် 15, 2016